US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

3.540 -0.080 (-2.21%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales ↗
GoodRx reported Q4 revenue of $198.6M, missing expectations. 2025 guidance projects $810M–$840M revenue and adjusted EBITDA of $270M–$286M. 
Via Benzinga
News headline image
GoodRx (NASDAQ:GDRX) Misses Q4 Revenue Estimates
Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $198.6 million. On the other hand, the company expects next... 
Via StockStory
News headline image
GoodRx Reports Fourth Quarter and Full Year 2024 Results
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
GoodRx Earnings: What To Look For From GDRX
Healthcare tech company GoodRx (NASDAQ:GDRX) will be announcing earnings results tomorrow before the bell. Here’s what investors should know. 
Via StockStory
News headline image
Assessing GoodRx Holdings: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
GoodRx Achieves HITRUST i1 Certification to Manage Data Protection and Mitigate Cybersecurity Threats
From GoodRx
Via Business Wire
News headline image
1 Healthcare Stock Primed for Growth and 2 to Avoid
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024.... 
Via StockStory
Topics Stocks
News headline image
1 Healthcare Stock Primed for Growth and 2 to Snub
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
News headline image
GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer
From GoodRx
Via Business Wire
News headline image
GoodRx Announces Date for Fourth Quarter and Full Year 2024 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
Scott Wagner Joins GoodRx Board of Directors
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
GoodRx Offering Free Telehealth Appointments to Los Angeles Residents Affected by Wildfires
From GoodRx
Via Business Wire
News headline image
GoodRx Unleashes “GoodRx for Pets,” Simplifying Access and Reducing Costs for Pet Medications
From GoodRx
Via Business Wire
News headline image
GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. Counties
From GoodRx
Via Business Wire
News headline image
GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, as New Chief Executive Officer
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel ↗
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction. 
Via Benzinga
News headline image
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals ↗
GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024. 
Via Benzinga
News headline image
GoodRx Reveals Americans Overspent on Weight Loss Medications by $200 Million This Year, Fills Still Surged
From GoodRx
Via Business Wire
News headline image
GOODRX ALERT: Bragar Eagel & Squire, P.C. is Investigating GoodRx Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why GoodRx Holdings Stock Was Sinking This Week ↗
The company is growing key fundamentals. However, the improvements weren't enough to impress the market. 
Via The Motley Fool
News headline image
GoodRx (GDRX) Q3 2024 Earnings Call Transcript ↗
GDRX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
GoodRx Reports Third Quarter 2024 Results
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
GoodRx to Participate in Upcoming Investor Conferences
From GoodRx Holdings, Inc.
Via Business Wire
News headline image
GoodRx Unveils New E-commerce Platform, Launches with Opill®
From GoodRx
Via Business Wire
News headline image
GoodRx Announces Exclusive Low Cash Price for QSYMIA®, the Leading Branded Once-Daily Oral Weight Management Medication for Adults
From GoodRx
Via Business Wire
News headline image
Ronald E. Bruehlman Joins GoodRx Board of Directors
From GoodRx
Via Business Wire
News headline image
GoodRx Announces New Affordability Programs for Menopause Hormone Therapies
From GoodRx
Via Business Wire
News headline image
GoodRx Partnering with Retail Pharmacies to Deliver Pay-Over-Time Option Directly to Consumers
From GoodRx
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >